| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Carbazochrome sodium sulfonate functions primarily as a capillary stabilizer rather than an antifibrinolytic agent. It reinforces vascular walls and prevents blood from leaking. It inhibits the enhancement of vascular permeability by histamine and bradykinin. It has no effect on platelets or the blood coagulation system.
|
|---|---|
| ln Vitro |
Bradykinin- and thrombin-induced [3H]IP3 production are inhibited in a concentration-dependent manner by carbazochrome (0.1–10 µM) [1]. Vasoactive drugs can generate an increase in permeability, which can be considerably inhibited by adding carbochrome (0.1-1 µM) half an hour before stimulation [1].
Carbazochrome sodium sulfonate is a synthetic hemostatic agent used to control bleeding. It reduces capillary permeability and fragility. It inhibits histamine- and bradykinin-induced vascular permeability. It has no effect on platelets or the coagulation system, distinguishing it from other hemostatic agents. |
| ln Vivo |
Severe pulmonary dysfunction brought on by intravenous contrast agent infusion can be prevented by Carro. In rats, radiation contrast agents can lessen lung dysfunction when carbazochrome (1–10 mg/kg) is injected intravenously [2].
Carbazochrome sodium sulfonate is used as a hemostatic agent in various medical and research settings. It is often prescribed in conditions where there is excessive bleeding or hemorrhage, such as in surgery or trauma. It reinforces vascular walls and prevents blood from leaking. It is a capillary stabilizer used in bleeding research. |
| Enzyme Assay |
Carbazochrome sodium sulfonate's activity is assessed using in vitro assays measuring its effects on capillary permeability and vascular stability. These assays typically involve measuring the leakage of dyes or other markers from blood vessels in response to permeability-inducing agents like histamine or bradykinin. The compound's ability to inhibit this leakage is quantified.
|
| Cell Assay |
Cellular assays for carbazochrome sodium sulfonate involve studying its effects on endothelial cells and vascular integrity. The compound's ability to stabilize endothelial cell junctions and reduce permeability can be assessed using in vitro models of the vascular barrier. Its effects on platelet function and coagulation are also evaluated to confirm its lack of activity on these systems.
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, body weight 180-230 g[2]
Doses: 1, 5 and 10 mg/kg Route of Administration: intravenous (iv) (iv)injection; injection 30, 60 or 90 minutes before injection of Ioxaglate (4 g I /kg, intravenous (iv) (iv)injection). Experimental Results: The increased vascular permeability of Ioxaglate was attenuated in a dose-dependent manner at doses of 1, 5 and 10 mg/kg, reaching statistical significance at doses of 5 and 10 mg/kg. In vivo animal model protocols for carbazochrome sodium sulfonate involve its administration to animal models of bleeding or increased vascular permeability. The compound's ability to reduce bleeding time, blood loss, and vascular leakage is assessed. Models of surgery, trauma, or induced hemorrhage are commonly used. |
| ADME/Pharmacokinetics |
Carbazochrome sodium sulfonate has a molecular formula of C10H11N4NaO5S and a molecular weight of 322.27. It is a water-soluble compound. Specific pharmacokinetic data is not extensively detailed in the available literature. As a hemostatic agent, it is typically administered parenterally.
|
| Toxicity/Toxicokinetics |
Carbazochrome sodium sulfonate is generally well-tolerated as a hemostatic agent. As a research compound, it is intended for research use only and not for human consumption. Its comprehensive toxicological profile may not be fully characterized.
|
| References |
|
| Additional Infomation |
Carbazochrome sodium sulfonate (CAS# 51460-26-5) is a synthetic hemostatic agent used in research. It is a capillary stabilizer that reduces vascular permeability and fragility. It has no effect on platelets or the coagulation system. It is not approved for clinical use as a therapeutic agent in most countries and is supplied as a research chemical.
|
| Molecular Formula |
C10H11N4NAO5S
|
|---|---|
| Molecular Weight |
322.27
|
| Exact Mass |
322.034
|
| CAS # |
51460-26-5
|
| Related CAS # |
Carbazochrome;69-81-8
|
| PubChem CID |
135705561
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
0.527
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
522
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PDZKPUQLQNDXMQ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C10H12N4O5S.Na/c1-14-7-4-8(15)6(12-13-10(11)16)2-5(7)3-9(14)20(17,18)19;/h2,4,9,15H,3H2,1H3,(H2,11,16)(H,17,18,19);/q;+1/p-1
|
| Chemical Name |
sodium;5-(carbamoyldiazenyl)-6-hydroxy-1-methyl-2,3-dihydroindole-2-sulfonate
|
| Synonyms |
Carnamid, Emex, Golcort, Hobat, Stopem; AC 17, AC-17, Adona, Adrenochrome sulfonate AC 17, Almetex, Carbazochrome sodium sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 49 mg/mL (~152.05 mM)
H2O : ~6.67 mg/mL (~20.70 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (7.76 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1030 mL | 15.5149 mL | 31.0299 mL | |
| 5 mM | 0.6206 mL | 3.1030 mL | 6.2060 mL | |
| 10 mM | 0.3103 mL | 1.5515 mL | 3.1030 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
